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Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal 
tract. The epidemiology of these tumors in Osijek-Baranja County is not known. The aim of this study is to 
determine the incidence of gastrointestinal stromal tumors (GIST) and anatomic localizations in Osijek-
Baranja County patients. In this study, we show the incidence of gastrointestinal stromal tumors (GISTs) in 
Osijek-Baranja County. We studied 65 cases of GIST diagnosed in Osijek-Baranja County in the period from 
January 1, 2004 to December 31, 2017. In this period, we registered 65 cases of GIST from which 29 females 
(44.6%) and 36 males (55.4%). The mean age at diagnosis was 66.9 years ranging from 37 to 86. Only 1.5% 
of tumors occurred before the age of 40 years. The crude incidence rate of GISTs was 1.47/100,000 
(1.26/100,000 for females and 1.70/100,000 for males). The age-standardized incidence rate was 0.76/100,000 
(0.60/100,000 for females and 0.98/100,000 for males). The annual European age-standardized incidence rate 
was 1.10/100,000 (0.86/100,000 for females and 1.44/100,000 for males). GISTs were mostly localized in the 
stomach (33 cases) and small intestine (20 cases), followed by peritoneum and omentum (8 cases), two in the 
pancreas, 1 in the rectum and 1 in other locations. Gastrointestinal stromal tumors are rare, but more common 
in the older population. The incidence rate was higher among men. These results will serve as reference for 
studying the patterns of descriptive epidemiology of GISTs in Osijek-Baranja County and the surrounding 
region. 
 




Gastrointestinalni stromalni tumori (GIST) najčešći su mezenhimalni tumori gastrointestinalnog trakta. 
Epidemiologija ovih tumora u Osječko-baranjaskoj županiji nije poznata. Cilj ove studije je odrediti pojavnost 
GIST-a i anatomskih lokalizacija kod oboljelih u Osječko-baranjskoj županiji. U ovoj studiji prikazujemo 
pojavnost gastrointestinalnih stromalnih tumora (GIST) u Osječko-baranjskoj županiji. Proučavali smo 65 
slučajeva GIST-a dijagnosticiranih u Osječko-baranjskoj županiji u razdoblju od 1. 1. 2004. do 31. 12. 2017. 
U ovom razdoblju zabilježili smo 65 slučajeva GIST-a, od čega je 29 žena (44,6%) i 36 muškaraca (55,4%). 
Prosječna dob bila je 66,9 godina, u rasponu od 37 do 86 godina. Samo 1,5% tumora pojavilo se prije 40-te 
godine. Nestandardizirana ili gruba stopa pojavnosti GIST-a iznosila je 1,47/100.000 (1,26/100.000 za žene i 
1,70/100.000 za muškarce. Dobno standardizirana stopa pojavnosti bila je 0,76/100.000 (0,60/100.00 za žene 
i 0,98/100.000 za muškarce). Godišnja europska dobno standardizirana stopa incidencije bila je 1,10/100.000 
(0,86/100.000 za žene i 1,44/100.000 za muškarce). Većina GIST-ova lokalizirana je u želucu (33 slučaja) i 
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tankom crijevu (20 slučajeva). Slijedi peritoneum i omentum (8 slučaja), dva u pankreasu, jedan rektalni i 
jedan na drugim lokacijama. Gastrointestinalni stromalni tumori rijetki su i češći u starijoj populaciji. Stopa 
pojavnosti viša je među muškarcima. Dobiveni rezultati poslužiti će kao reference za proučavanje obrazaca 
opisne epidemiologije GIST-a na području Osječko-baranjske županije i okolice. 
 






Gastrointestinal stromal tumors (GISTs) are the 
most common non epithelial tumors of the 
gastrointestinal (GI) tract (1-3% of all gastrointestinal 
malignancies). They are mostly localized in the 
stomach (60-70%), followed by small intestine (20-
30%), and colon and rectum (5-10%). GIST develops 
outside the digestive tube (≤ 5%) in the mesentery, 
omentum or retroperitoneum. Most GISTs present 
asymptomatically. They are best identified by 
computed tomography (CT), and most smears are 
positive for CD117 (C-Kit), CD34, and/ or DOG-1. 
There are many classification systems that calculate 
based on tumor size, mitotic rate, location, and 
perforation.1,2 Histological origin, classification, 
diagnostic criteria and their biological potential are still 
controversial. Today, the prevailing attitude is that 
GIST originate from Cajal cells (pacemaker cells of the 
GI tract), or from a less-differentiated stem or 
precursor cells that can develop into interstitial cells of 
Cajal (ICC). GISTs show a wide variety of clinical 
behavior ranging from benign to frankly malignant, 
making the outcome totally unpredictable. Metastases 
commonly develop in the abdominal cavity and liver; 
rarely do metastases develop in bones, soft tissues, 
lymph nodes, lungs and skin.3 
GISTs usually occur in older adults, with a mean 
age of about 60-65 years and somewhat less frequently 
in diseases equal in men and women.4 Symptoms 
associated with GIST vary depending on the location 
and size of the lesion. Small GISTs often have no 
symptoms. An increase in the size of a GIST can 
develop mass-related symptoms, such as abdominal 
pain, discomfort in the digestive system, and a feeling 
of fullness in the abdomen. 
In GIST, the most common clinical manifestation 
was GI bleeding resulting from mucosal ulceration, 
which occurs in almost half of GIST cases. GI bleeding 
can change the texture of the stool to dark red or black. 
In addition, bleeding leads to occasional vomiting of 
blood. Chronic blood loss can lead to anemia that 
causes fatigue and in some cases tachycardia. GI 
bleeding (58%) and abdominal pain (61%) are more 
common in gastric GISTs however other acute 
abdominal symptoms are more common in jejunal 
(40%) and ileal GIST (60%).5 
The gold standard of GIST treatment is surgical 
resection by laparoscopy, however if the patient is 
unstable, then an open laparotomy method is the 
preferred method of treatment. 
Laparoscopic surgery (LSG) is recommended for 
GISTs smaller than 5 cm located in the stomach and 
small intestine.6 The European Society of Medical 
Oncology Clinical Practice Guidelines consider any 
GIST to be potentially malignant and recommend 
surgical treatment of all GISTs without metastases.7 
However, not all patients are diagnosed at an early 
stage; 10%–25% of patients have metastatic disease. 
Tumors that have spread are more aggressive or have 
progressed locally may benefit from combined 
targeted therapies in combination with surgery.8 
Survival after complete surgical resection ranges from 
48% to 80% after 5 years. If resection is not completed, 
only 9% of patients survive an average of 12 
months.9,10 
Retrospective assessment of GISTs incidence and 
other clinical characteristics prior to 2000 is relatively 
difficult because of problems with identification and an 
incomplete understanding of their origin. A large 
number of tumors previously diagnosed as GI 
leiomyoma, leiomyosarcoma and leiomyoblastoma, as 
many tumors that were previously considered 
neurofibromas or Schwannoma.11 The situation has 
changed since the late 1990s with observations on the 
origin of GIST in the ICC and the role of c-Kit proto-
oncogene mutations. More than 90% of malignant 
GISTs have aberrant signal transmission mediated by 
KIT.12 In the past few years, GIST has become a 
prototype neoplasm that responds to therapy directed 
against the target molecule receptor tyrosine kinase Kit 
(CD117), which induce cell proliferation.13 New 
evidence-based treatment guidelines recommend 
imatinib as first-line therapy in cases of marginally 
respectable pathology-confirmed GISTs, with surgery 
and postoperative imatinib administration advised if 
imatinib response improves resectability.14,15 The 
epidemiology of these tumors in the Osijek-Baranja 
County has not been known.  
The aim of this study was to determine the 
incidence of GIST and anatomic localizations in 
Osijek-Baranja County patients. 
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Materials and methods 
 
In this study, we show the incidence of 
gastrointestinal stromal tumors (GISTs) in Osijek-
Baranja County. We studied 65 cases of GIST 
diagnosed in Osijek-Baranja County in the period from 
January 1, 2004 to December 31, 2017. Data were also 
derived from hospital discharge notifications called 
“Onco Type Cards” and outpatient “Malignant 
Neoplasm Notification”, submitted to the Institute of 
Public Health for Osijek-Baranja County and the 
Croatian National Cancer Registry. All cases were 
verified by a histopathology and immunohistochemical 
examination, also confirming the previously 
established histological diagnosis of GIST. The 
approval of the Ethics Committee of the Clinical 




Data were encoded according to the International 
Classification of Diseases Tenth Revision (ICD-10) 
and ICD-O-3, i.e. code M8936/0-M8936/3.16 The crude 
rate of GIST incidence was calculated on the basis of the 
2001 and 2011 Croatian census. Age-standardized 
incidence rates of GIST were calculated by the direct 
standardization method, using the World Standard 
Population and the European Standard Population.17 





In Osijek-Baranja County, in a fourteen-year period 
from 2004 to 2017 there were 65 registered patients 
with GISTs. Of the total number of GIST 29 were 
females (44.6%) and 36 males (55.4%). The mean age 
at diagnosis was 66.9 years ranging from 37 to 86. 
Only 1.5% of tumors occurred before the age of 40 
years. 98.5% of all GIST cases were over 40 years, 
more likely between 60-79 years of age (Figure 1).  
In the considered period, in the Osijek-Baranja 
County crude incidence rate of GISTs was 
1.47/100,000 (1.26/100,000 for females and 
1.70/100,000 for males). The age-standardized (ASR 
World) incidence rate was 0.76/100,000 (0.60/100,000 
for females and 0.98/100,000 for males). The annual 
European ASR was 1.10/100,000 (0.86/100,000 for 
females and 1.44/100,000 for males). The incidence 
rate was higher among men (Figure 2).  
The most frequent sites of tumor primary 
occurrence were the stomach 33 (50.8%) and small 
intestine 20 (30.8%), followed peritoneum and 
omentum 8 (12.3%), 2 (3.1%) pancreas, 1 (1.5%) in 
the rectum and 1 (1.5%) by other locations of tumor, 
with almost similar distribution by female and male 
(Figure 3). Forty-nine (75.4%) of GISTs were 




Figure 1 Distribution of GIST patients by age and sex in Osijek-Baranja County, 2004 - 2017 
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Figure 2 Age-standardized (ASR World) incidence rates of GIST by sex in Osijek-Baranja County, 2004 - 2017 
Slika 2. Dobna standardizirana stopa (ASR World) incidencije GIST-a po spolu u Osječko-Baranjskoj županiji, 
2004. – 2017.  
 
Figure 3 Localization of gastrointestinal stromal tumor (GIST) in female and male patients in Osijek-Baranja 
County, 2004 - 2017 
Slika 3. Lokalizacija gastrointestinalnih stromalnih tumora (GIST) kod ženskih i muških bolesnika u Osječko-
Baranjskoj županiji, 2004. – 2017. 
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This study included 65 patients (36 male and 29 
female). Their mean age at diagnosis was 66.9 years 
(ranging from 37 to 86 years). In their research, 
Cavaliere and associates18 reported that GIST can 
occur at any age, peaking around age 60, and that it 
affects men and women equally. Miettinen and 
associates19 reported that GISTs were rare before the 
age of 40 years and very rare in children and were 
mildly predominant in men however other research 
reports did not show gender differences.20 
The incidence of GISTs is not known for all 
populations, most data refer to Caucasian industria-
lized populations, and prior studies in many countries 
often provide conflicting results. Some of the papers 
emphasize the differences in GIST incidence before 
and after the consensus on GIST detection and 
classification.21 It is primarily a disease of older adults, 
with the median age at diagnosis reported in the 
seventh decade of life.22 Despite the described 
problems, several studies have been published on the 
basis of long-term population studies on the incidence 
and survival on GIST. For example, Goettsch et al. 
showed that the annual incidence of GIST in the 
Netherlands dramatically increased between the years 
1995 and 2003 from 2.1 to 12.7 per million inhabitants, 
whereas the annual incidence of GIST-like tumors, 
mostly leiomyomas and leiomyosarcomas, decreased 
from 18.7 to 12.7 per million inhabitants. This was 
attributed to an improvement in the understanding of 
GIST pathobiology, detection, and identification.23 A 
study in western Sweden showed that the annual 
incidence of GIST was about of 1.45/100,000 
inhabitants.24 Epidemiology data from the first 
population-based study in Iceland from 1990 to 2003 
(300,000 inhabitants) estimated an overall world ASR 
of 1.1/100,000.25 Recent population studies from the 
GIST Register in the Czech Republic and Slovakia 
evaluate the annual crude incidence between years 
2001-2005 was 0.52/100,000 inhabitants. The annual 
European ASR and World ASR were 0.44 and 
0.31/100,000 inhabitants.26 A study based on 
pathology reports from 38 hospitals in Korea (2003-
2004) reported that the incidence of GISTs was 
approximately 1.6-2.2/100,000 inhabitants.27 The 
results of the first Asian nation-wide cancer registry-
based study (1998-2008) of GISTs showed that the 
annual incidence of GISTs in Taiwan ranged from 
1.13-1.97/100,000 inhabitants.28 The incidence of 
these tumors is variable from as low as 4.3-6.8 per 
million to as high as 19-22 cases per million, with a 
high degree of variability between different geographic 
areas.29 GIST showed a female predilection in 
France.30 Recent studies in the USA noted an increase 
in the incidence of the GIST with Ma et al. reporting a 
42% increase in the diagnosis of GIST from 2001 to 
2011.31-33 The overall incidence of GISTs in the 50 
states of the United States from 2001-2015 was 0.70 
per 100,000 population per year with a slight upward 
trend noted annually.34 Some reports do exist regarding 
the incidence of GIST in 3 different regions of China: 
0.43 per 100,000 population in Shanxi,35 2.11 per 
100,000 population in Shanghai,36 and 1.55 per 
100,000 population in Taiwan.37 In addition, due to 
racial and weight differences between patients from 
Eastern and Western countries, there also may be 
differences regarding tolerance to the targeted agent 
therapy of the same dosage.38 Given the different study 
time periods and the lack of confirmation by KIT 
immuno-histochemical staining in some studies, it is 
difficult to compare the incidence rates of GISTs across 
different countries; however, the published literature to 
date showed that the incidence rates of GISTs in 
different countries appeared to fall in a similar range.39    
GIST therapy is a prototype of treatment based on 
the "single target molecule" principle where the target 
enzyme is an abnormal protein of tyrosine kinase 
activity, the so-called KIT protein.40 
Osijek-Baranja County is situated in north-eastern 
Croatia and takes up a total area of 4,155 km2, which 
is 7.3% of Croatia’s territory. According to the 2011 
census, Osijek-Baranja County has a population of 
305,032; 158,141 (52%) are female and 146,891 
(48%) are male.39 This population-based study shows 
that the incidence of GIST in Osijek-Baranja County is 
comparable to that reported in other European 
countries. It is very similar to the rate of population 
based studies in the province of Modena in Italy 
(0.66/100,000),41 or in Girona in Spain (0.65-
0.90/100,000),28 and significantly higher than the rate 
that shows the registry for GIST in the Czech Republic 
and Slovakia.26 The most common localization of the 
GISTs in our study was the stomach and small 
intestine, what is also observed in some other 
studies.41,42 Gender, race, and location distribution of 
GISTs are also uncertain.43,44 
In this study, the crude incidence rate of GISTs          
was 1.47/100,000 (1.26/100,000 for females and 
1.70/100,000 for males). The age-standardized (ASR 
World) incidence rate was 0.76/100,000 (0.60/100,000 
for females and 0.98/100,000 for males).  
Gastrointestinal stromal tumors are rare, but more 
common in the older population. The incidence rate 
was higher among men. These results will serve as 
reference for studying the patterns of descriptive 
epidemiology of GISTs in the Osijek-Baranja County 
and the surrounding region. 
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